As ICIs have demonstrated significant success in cancers such as melanoma, lung, and renal cancer, their role in BC, particularly in overcoming immune evasion mechanisms in MIBC, is gaining increasing attention [10,11], especially in combination with the blockade of the NKG2A pathway [12]. Here, KLRC1 is linked to breast cancer.